CellCentric’s Inobrodib Exhibits Novel Mechanism of Action with Potential to Treat Number of Hematological Malignancies; New Data Published in Cancer Cell

On November 22, 2023, CellCentric, a UK-based biotechnology company, announced publication of a cornerstone paper in Cancer Cell.  The work builds on pre-clinical and clinical collaborations, notably with Professor Tim Somervaille of the Cancer Research UK Manchester Institute. The new paper, titled, “Therapeutic Targeting of EP300/CBP by Bromodomain Inhibition in Hematologic Malignancies,” reports on the therapeutic mechanism of inobrodib and relevant clinical results.The open-access November 22 paper demonstrates inobrodib’s action as a potent and selective inhibitor of the bromodomains of p300 and CBP, and shows how it has a profound impact on the regulatory elements which control expression of key cancer driver genes.

Login Or Register To Read Full Story